Advertisement

The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.

Follow us on Twitter @CR_AACR!

From the Current Issue

  • FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress
    Translational Science
    FGF Trapping Inhibits Multiple Myeloma Growth through c-Myc Degradation–Induced Mitochondrial Oxidative Stress
    Roberto Ronca, Gaia C. Ghedini, Federica Maccarinelli, Antonio Sacco, Silvia L. Locatelli, Eleonora Foglio, Sara Taranto, Elisabetta Grillo, Sara Matarazzo, Riccardo Castelli, Giuseppe Paganini, Vanessa Desantis, Nadia Cattane, Annamaria Cattaneo, Marco Mor, Carmelo Carlo-Stella, Angelo Belotti, Aldo M. Roccaro, Marco Presta and Arianna Giacomini
    Cancer Res June 1 2020 80 (11) 2340-2354; DOI:10.1158/0008-5472.CAN-19-2714

    This study provides new insights into the mechanisms by which FGF antagonists promote multiple myeloma cell death.

  • Convergence and Technologies
    Model-Based Inference and Classification of Immunologic Control Mechanisms from TKI Cessation and Dose Reduction in Patients with CML
    Tom Hähnel, Christoph Baldow, Joëlle Guilhot, François Guilhot, Susanne Saussele, Satu Mustjoki, Stefanie Jilg, Philipp J. Jost, Stephanie Dulucq, François-Xavier Mahon, Ingo Roeder, Artur C. Fassoni and Ingmar Glauche
    Cancer Res June 1 2020 80 (11) 2394-2406; DOI:10.1158/0008-5472.CAN-19-2175

    This mathematical modeling approach provides strong evidence that different immunological configurations in patients with CML determine their response to therapy cessation and that dose reductions can help to prospectively infer different risk groups.

  • Priority Reports
    ATM Loss Confers Greater Sensitivity to ATR Inhibition Than PARP Inhibition in Prostate Cancer
    Shahrzad Rafiei, Kenyon Fitzpatrick, David Liu, Mu-Yan Cai, Haitham A. Elmarakeby, Jihye Park, Cora Ricker, Bose S. Kochupurakkal, Atish D. Choudhury, William C. Hahn, Steven P. Balk, Justin H. Hwang, Eliezer M. Van Allen and Kent W. Mouw
    Cancer Res June 1 2020 80 (11) 2094-2100; DOI:10.1158/0008-5472.CAN-19-3126

    ATM loss occurs in a subset of prostate tumors. This study shows that deleting ATM in prostate cancer models does not significantly increase sensitivity to PARP inhibition but does sensitize to ATR inhibition.

See the Table of Contents

Recent Reviews

OnlineFirst Articles

Load more
Advertisement

Back to top